Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170867-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $49.90 | |
| Ab170867-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $229.90 | |
| Ab170867-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $589.90 | |
| Ab170867-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $949.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Inebilizumab (anti-CD19) - Primary antibody, specific to CD19, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Antibody deficiency due to defect in CD19 antibody; Antibody deficiency due to defect in CD19, included antibody; AW495831 antibody; B lymphocyte antigen CD19 antibody; B lymphocyte surface antigen B4 antibody; B-lymphocyte antigen CD19 antibody; B-lympho |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | CD19 |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | BINDING AGENT |
| Mechanism of action | BINDING AGENT of B-lymphocyte antigen CD19 binding agent |
| Product Description | Inebilizumab (anti-CD19) is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab (anti-CD19) can be used for multiple sclerosis and neuromyelitis optica research. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 28.4 kDa (Light Chain) & 52.1 kDa (Heavy Chain), under reducing conditions; 181.9 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1299440-37-1 |
Inebilizumab (anti-CD19) (Ab170867) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD19 with Inebilizumab (anti-CD19) (Ab170867) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156250).
Inebilizumab (anti-CD19) (Ab170867) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD19 (red) with Inebilizumab (anti-CD19) (Ab170867) conjugated with biotin and detected with SA-PE (rp156250). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Inebilizumab (anti-CD19) (Ab170867) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD19 (red) with Inebilizumab (anti-CD19) (Ab170867). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Inebilizumab (anti-CD19) (Ab170867) - SEC
The purity of Inebilizumab (anti-CD19) (Ab170867) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1001473 | Certificate of Analysis | Nov 01, 2023 | Ab170867 |
| ZJ23F1001474 | Certificate of Analysis | Nov 01, 2023 | Ab170867 |
| 1. Tedder TF, Isaacs CM. (1989) Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily.. J Immunol, 143 (2): (712-7). [PMID:2472450] |
| 2. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K et al.. (2010) B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.. J Pharmacol Exp Ther, 335 (1): (213-22). [PMID:20605905] |
| 3. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R et al.. (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.. Cancer Res, 68 (19): (8049-57). [PMID:18829563] |
| 4. Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, Marafioti T, Britten CE, Havenith CEG, Chivers S et al.. (2018) ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.. Blood, 131 (10): (1094-1105). [PMID:29298756] |
| 5. Zhou, L J LJ, Ord, D C DC, Omori, S A SA and Tedder, T F TF.. (1992) Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes.. Immunogenetics, [PMID:1370948] |
| 6. Carter, R H RH and Fearon, D T DT.. (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.. Science (New York, N.Y.), (3): [PMID:1373518] |
| 7. Kozmik, Z Z, Wang, S S, Dörfler, P P, Adams, B B and Busslinger, M M.. (1992) The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP.. Molecular and cellular biology, [PMID:1375324] |
| 8. Bradbury, L E LE, Kansas, G S GS, Levy, S S, Evans, R L RL and Tedder, T F TF.. (1992) The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:1383329] |
| 9. Matsumoto, A K AK and 5 more authors.. (1991) Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19.. The Journal of experimental medicine, (1): [PMID:1702139] |
| 10. Stamenkovic, I I and Seed, B B.. (1988) CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail.. The Journal of experimental medicine, (1): [PMID:2459292] |
| 11. Buhl, A M AM, Pleiman, C M CM, Rickert, R C RC and Cambier, J C JC.. (1997) Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for PI3-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization.. The Journal of experimental medicine, (1): [PMID:9382888] |
| 12. Brooks, S R SR, Li, X X, Volanakis, E J EJ and Carter, R H RH.. (2000) Systematic analysis of the role of CD19 cytoplasmic tyrosines in enhancement of activation in Daudi human B cells: clustering of phospholipase C and Vav and of Grb2 and Sos with different CD19 tyrosines.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:10706702] |
| 13. Kuroki, K K and 10 more authors.. (2002) Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese.. Genes and immunity, [PMID:12215898] |
| 14. Wang, Yue Y and 5 more authors.. (2002) The physiologic role of CD19 cytoplasmic tyrosines.. Immunity, [PMID:12387743] |
| 15. Martin, Joel J and 121 more authors.. (2004) The sequence and analysis of duplication-rich human chromosome 16.. Nature, (23): [PMID:15616553] |
| 16. Shoham, Tsipi T, Rajapaksa, Ranjani R, Kuo, Chiung-Chi CC, Haimovich, Joseph J and Levy, Shoshana S.. (2006) Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments.. Molecular and cellular biology, [PMID:16449649] |
| 17. van Zelm, Menno C MC and 10 more authors.. (2006) An antibody-deficiency syndrome due to mutations in the CD19 gene.. The New England journal of medicine, (4): [PMID:16672701] |
| 18. Zugmaier, Gerhard G, Klinger, Matthias M, Schmidt, Margit M and Subklewe, Marion M.. (2015) Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.. Molecular immunology, [PMID:25883042] |
| 19. Gallagher, Sandra S and 7 more authors.. (2016) MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19.. Arthritis & rheumatology (Hoboken, N.J.), [PMID:26606525] |
| 20. Gallagher, Sandra S and 7 more authors.. (2016) Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice.. International immunopharmacology, [PMID:27163209] |
| 21. Teplyakov, Alexey A, Obmolova, Galina G, Luo, Jinquan J and Gilliland, Gary L GL.. (2018) Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold.. Proteins, [PMID:29490423] |
| 22. Wang, Michael and 24 more authors.. (2020) KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.. The New England journal of medicine, (2): [PMID:32242358] |
